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Abstract 
The emergence of treatment resistant sub-clones is a key feature of relapse in 
multiple myeloma. Therapeutic attempts to extend remission and prevent relapse include 
the maximisation of response and use of maintenance therapy. We used whole exome 
sequencing to study the genetics of paired presentation and relapse samples from 56 newly 
diagnosed patients, following induction therapy, randomised to receive either lenalidomide 
maintenance or observation as part of the Myeloma XI trial. Patients included were 
considered high risk, relapsing within 30 months of maintenance randomisation. Patients 
achieving a complete response had predominantly branching evolutionary patterns leading 
to relapse, characterised by a greater mutational burden, an altered mutational profile, bi-
allelic inactivation of tumour suppressor genes, and acquired structural aberrations. 
Conversely, in patients achieving a partial response the evolutionary features were 
predominantly stable with a similar mutational and structural profile seen at both time points. 
There were no significant differences between patients relapsing after maintenance 
lenalidomide versus observation. This study shows that the depth of response is a key 
determinant of the evolutionary patterns seen at relapse.  
Clinical trial: NCT01554852  
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Introduction 
Multiple myeloma (MM) results from the malignant transformation of a normal plasma 
cell and has a mutational load, which lies in an intermediate position between genetically 
simple malignancies such as chronic myelogenous leukemia and the more complex solid 
cancers (1, 2). As such, MM provides an excellent model system with which to understand 
the mutational and evolutionary processes underlying disease relapse. MM is a genetically 
diverse condition, which is manifested by variations in clinical outcome even in uniformly 
treated populations (3, 4).  
The treatment of newly diagnosed (ND) MM has improved over the last decade 
following the introduction of immunomodulatory drugs and proteasome inhibition, which 
together with autologous stem cell transplantation have increased the median overall 
survival from 3 to 8 years (5-7). However, relapse remains frequent, and to improve 
outcomes further strategies have been designed to eliminate the residual clonal cells that 
mediate relapse (8-10). In this context an important strategy has been the use of 
maintenance therapy with lenalidomide (11-13). This agent is well tolerated and has a 
bifunctional mode of action directly killing the tumour cells and enhancing the immune 
response to the malignant plasma cells that is mediated by directing Aiolos and Ikaros to the 
proteasome for degradation (14-17).  
Understanding the features of residual cells that lead to relapse is an important 
challenge, however, this is technically difficult especially in patients who have achieved 
stringent complete responses. One way of understanding the characteristics of cells in 
remission is to study the characteristics of cells at relapse. Previous studies of the genetic 
features of paired presentation and relapse samples have shown that after intensive 
chemotherapy bi-allelic loss of tumor suppressor genes, in particular TP53 and the 
deregulation of MYC by structural chromosomal changes are important features (18). In 
addition to mutational change, subclonal structure also varies at relapse with three main 
patterns having been described; branching, linear and shifting patterns of clonal dominance 
(18-23), Table 1. Such analyses have not, however, studied uniformly treated patients for 
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whom the depth of response or treatment information is available. To address the impact of 
maintenance and response depth on mutational patterns and clonal structure at relapse we 
performed whole exome sequencing (WES) on paired presentation and relapse samples 
from 56 NDMM patients, 30 of whom had received maintenance lenalidomide and 26 who 
did not.  All were treated at first presentation with a triple induction regimen containing an 
immunomodulatory agent, cyclophosphamide, and dexamethasone making this the largest 
analysis of genetic evolution in a uniformly treated series of MM patients to date. 
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Methods  
Samples were selected from NDMM patients enrolled into the Myeloma XI trial 
(NCT01554852) for whom adequate DNA volumes were available (24). The study was 
undertaken with written informed consent from patients and ethical approval was obtained 
from the Oxfordshire Research Ethics Committee (MREC 17/09/09, ISRCTN49407852). A 
nested case control analysis was performed on 56 patients who received either lenalidomide 
maintenance (n=30) or underwent observation (n=26) and subsequently relapsed (25, 26), 
Supplementary Figure 1. All patients included had phenotypical high risk disease, defined 
as relapse within 30 months of maintenance randomisation, irrespective of classical genetic 
risk status and best response. The median time from trial entry to relapse was 19 months, 
notably shorter than the Myeloma XI trial reported PFS of 35.9 and 32.9 months for patients 
treated with lenalidomide and thalidomide induction, respectively (27). Response was 
determined using International Myeloma Working Group (IMWG) criteria and a near CR 
(nCR), defined as no detectable paraprotein, a normal light chain ratio but where 
immunofixation and or bone marrow sampling was not performed or if immunofixation was 
positive. Prior to relapse, 21% (12/56) achieved a complete response (CR), 21% (12/56) a 
nCR, 42% (23/56) a very good partial response (VGPR), and 16% (9/56), a partial response 
(PR). To determine the impact of response on the genetic landscape at relapse we grouped 
patients according to the best response achieved prior to relapse, complete responders 
(CR/nCR) and non-complete responders (VGPR/PR). Clinical characteristics were well 
matched between the maintenance groups, Table 2. The characteristics of patients 
according to induction regimen were also well matched, Supplementary Table 1.  
DNA was isolated from plasma cells following selection using CD138+ MACSorting 
(Miltenyi Biotech, Bisley, United Kingdom) from bone marrow aspirate samples. Control 
DNA was obtained from peripheral blood samples. Libraries for WES were prepared using 
the SureSelectQXT sample prep kit and the SureSelect Clinical Research Exome kit 
(Agilent), with additional baits covering the immunoglobulin and MYC loci, as previously 
described (28).  Paired-end sequencing was performed to a median sequencing depth of 
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122x for tumour samples and 58x for controls using a HiSeq2500 (Illumina). Single 
nucleotide variants, including those of tumour suppressor genes and oncogenes were 
determined using Strelka (v1.0.14) and MuTect (29, 30). The distribution of mutant alleles 
determined by the variant allele frequency (VAF) was mapped using the R package 
SciClone (31). Cancer clonal fractions (CCF) were calculated for all mutations and plotted 
using Kernal density estimation to infer clonal structure at presentation and relapse (32).    
Copy number was assessed using both multiplexed ligation-dependant probe 
amplification (MLPA) (SALSA MLPA P425-B1 multiple myeloma probemix, MRC Holland, 
Amsterdam, The Netherlands) and the bioinformatics assessment tool Sequenza (version 
2.1.2) (33, 34).  Paired MLPA and Sequenza data was available for 90/112 (80%) tumour 
samples, with a consensus between MLPA and Sequenza being seen in 85/90 samples 
(94%).  For the five patients where a mismatch was observed Sequenza was used to call 
the copy number profile. Translocations were determined using MANTA (version 0.29.3) 
(35).  For 46% (51/112) of patient samples, translocations involving the immunoglobulin 
heavy chain (IGH) were also assessed using multiplexed qRT-PCR (36). A consensus 
between MANTA and qRT-PCR was observed in 84% (43/51). In the 8 patients where a 
mismatch was seen, the integrative genomics viewer (IGV) was used to confirm or exclude 
the translocation. All suspected bi-allelic copy number abnormality (CNA) events were 
confirmed by manual interrogation of BAM files using IGV. Bi-allelic inactivation was also 
called in patients with evidence of a non-synonymous mutation with mono-allelic loss or a 
single mutation with a VAF of ≥80%. A summary of the methods, bioinformatics tools and 
filters used to complete this analysis are covered in Supplementary Figure 2.  
Statistical analysis was performed using GraphPad Prism version 7.01 and R version 
3.2.1. A P-value of 0.05 (two sided) was considered statistically significant. Wilcoxon 
matched-pairs signed rank tests were conducted to determine significance between paired 
data sets, including the mutational load at presentation/relapse and PFS according to 
maintenance allocation, depth of response and induction treatment. Fisher’s exact test was 
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used to determine differences between two nominal variables, including the change in 
mutational profile at presentation/relapse and evolutionary mechanism leading to relapse.   
Results 
Relapse is characterised by a change in mutational spectrum   
At presentation genes mutated in >10% of patients were NRAS (23%, n=13), KRAS 
(23%, n=13), and DIS3 (13%, n=7), Figure 1A. At relapse TP53 was also seen in >10% of 
patients (11%, n=6). We examined genes that have previously been shown to be recurrently 
mutated in myeloma, including tumour suppressor genes, epigenetic modifiers, and genes 
within the RAS, NFκB and apoptosis pathways, the results of which are summarized, Figure 
1B (18, 28, 37-44). Non-synonymous mutations were seen in one or more of these genes in 
79% (44/56) of patients at presentation and 80% (45/56) at relapse. Importantly, gain and/or 
loss of one or more of these lesions at relapse was seen in 37% of patients (21/56), with 
21% (12/56) of patients gaining a new lesion, 11% (6/56) losing a lesion, and 5% (3/56) both 
gaining and losing lesions. The most common new mutations at relapse were KRAS and 
PRDM1 both seen in 5% of patients (3/56) and NRAS and TP53 each seen in 4% (2/56). 
However, mutations in KRAS and NRAS were just as likely to be lost at relapse with 5% 
(3/56) of patients losing KRAS mutations and 4% (2/56) losing NRAS, Figure 1C. The most 
commonly mutated pathway was the RAS-MAPK pathway, with mutations of one or more of 
NRAS, KRAS, BRAF, NF1, and EGFR being seen in 57% (33/56) of patients at some point 
during the disease course. Loss of one or more of these mutations was noted in 9% (5/56) 
of patients at relapse whilst new mutations were seen in 13% (7/56). The majority of these 
new mutations were clonal (CCF>80%) and all had a CCF of >20% (range 0.29 – 1), 
Supplementary Figure 3. The results of these mutational studies are consistent with there 
being important changes in subclonal structure at relapse, rather than the simple 
accumulation of new mutations.  The profile of mutations at presentation and relapse in 
patients who received lenalidomide or thalidomide induction was well matched, 
Supplementary table 2.  
Acquired structural change is a frequent feature of relapse 
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We interrogated regions of recurrent CNA that are known to be associated with 
prognosis; 1p32.3 (FAF1/CDKN2C), 1p12 (FAM46C), 13 (RB1), 14q (TRAF3), and 17p 
(TP53). Copy number loss of ≥1 of these regions was seen in 63% (35/56) of patients at 
presentation and 59% (33/56) at relapse, Supplementary Figure 4. A change in the profile 
at relapse was evident, with regions of loss seen at presentation returning to a diploid status 
seen in 9% (5/56) of patients and new losses being seen in 13% (7/56). These features are 
again consistent with an alteration in subclonal structure and a change in the nature of the 
dominant clone being seen at relapse.  
Gain(1q) was the most common new event at relapse, occurring in 13% (7/56) 
patients. Secondary translocations to chromosome 8q, the site of MYC, also occurred more 
frequently at relapse, increasing from 21% (12/56) to 27% (15/56), Supplementary Table 3 
(45). Consistent with translocations to MYC being late events five patients had evidence of 
two separate MYC translocations at relapse. All patients with gain(1q) or tMYC at 
presentation had evidence of the lesion at relapse illustrating the driver status.  
Bi-allelic inactivation of tumour suppressor genes located at sites of recurrent CNA 
are likely to be relevant mediators of relapse. We show that bi-allelic inactivation events of 
RB1, TRAF3, and TP53 are important with 18% (10/56) of patients having evidence of bi-
allelic inactivation of ≥1 gene at relapse, in comparison to 14% (8/56) at presentation. One 
patient lost evidence of bi-allelic inactivation of TP53 at relapse due to expansion of a 
different subclone also characterized by a TP53 mutation which had a higher CCF at 
relapse (0.55 vs 0.83).  
Relapse following a complete response is characterised by a greater mutational load 
and a change in genetic profile 
Patients achieving a CR had a significantly higher non-synonymous mutational load 
at relapse with a median of 59 mutations compared to 40 at presentation (p=<0.001).  Non-
CR patients had a similar mutational load at relapse with a median of 39 mutations at both 
time points (p=0.63). Similar patterns were also seen in patients receiving lenalidomide 
maintenance or not, Supplementary Table 4.  
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By comparing the profile of known recurrently mutated genes we show that 67% 
(16/24) of CR cases had a change in mutational profile at relapse compared to only 25% 
(8/32) of non-CR cases (p=0.003), Figure 2A. These findings were a feature of both the 
observation and lenalidomide maintenance series, Figure 2B and C. Consistent with the 
mutation profile changes described, gain and loss of the structural lesions del(1p), del(13), 
del(14), del(17p), gain (1q), and tMYC at relapse was more common in the CR series, with 
42% (10/24) of patients having a change in the profile of these aberrations compared to  
28% (9/32) of non-CR patients, Supplementary Figure 5.  The changes in mutational load 
could not be linked to a change in the number of clones predicted by SciClone clustering, 
where a median number of 7 clones was seen at relapse in both the CR and non-CR series, 
Figure 3. The same findings were noted for all 56 patients and according to maintenance 
strategy. No patient had evidence of the loss or gain of >2 mutational clusters at relapse, 
further suggesting that a change in the number of clones is not a major cause for mutational 
load change, Supplementary Table 5.  
Lenalidomide maintenance has no impact on the mutational profile at relapse.  
There was no specific mutational, copy number or structural feature which 
characterized patients who received lenalidomide maintenance compared to those being 
observed. Of patients who received lenalidomide maintenance, 83% (25/30) had a mutation 
in one or more of the recurrently mutated myeloma genes at some point during the disease 
course compared to 85% (22/26) of patients being observed. Gain and/or loss of one or 
more mutation at relapse, including those in genes implicated in immunomodulatory agent 
mechanism of action were seen in 43% (13/30) of lenalidomide maintenance patients and 
35% (9/26) of the observation patients (figure 1B).  
We did not identify a mutational signal consistent with the selection of clones 
carrying mutations associated with the acquired resistance to lenalidomide. Five patients 
had mutations in DDB1 (n=2), SLC16A1 (n=2), and CRBN (n=1) but these were not 
confined to the lenalidomide maintenance cases nor were they seen exclusively at relapse 
(figure 1B). Mutations in other genes linked to lenalidomide mechanism of action including 
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regulator of cullins 1, cullin-4A, Ikaros, Aiolos, and Basigin were not found at presentation or 
relapse in any patient (14, 46-48). Mutations in MYC and IRF4, transcription factors known 
to be downregulated in response to immunomodulation were seen in 2% (n=1) and 4% 
(n=2) of patients respectively. However, consistent with an acquired mutation having a 
possible role in drug resistance we identified a patient, exposed to 8 months of lenalidomide 
maintenance who achieved flow cytometric MRD negativity (minimum 5 x 105 cells 
interrogated) that went on to develop a novel CRBN mutation (p.Cys326Gly) at relapse 
consistent with the emergence of resistance due to mutation at the immunomodulatory 
molecule binding site. The mutation was also present in a dominant clone, with a CCF of 
0.71, further suggesting its presence may have impacted on the fitness of the tumour in 
relation to immunomodulatory treatment pressure, Supplementary Figure 6.   
Branching evolution is the predominant process leading to relapse, particularly in 
patients achieving a deep treatment response 
We observed three main evolutionary patterns at relapse; branching, linear, and 
stable. Branching evolution was characterised by both gain and loss of mutational clusters 
and was the predominant pattern, seen in 66% (37/56) of all cases, Figure 4A. Linear 
evolution, characterised only by the gain of mutations at relapse was seen in 20% (11/56) of 
cases, Figure 4B. The remaining 14% (8/56) had either the same mutational profile at both 
time points and were classified as stable progression (n=7) or displayed a loss of a 
mutational cluster at relapse, classified as stable progression with clone loss (n=1), Figures 
4C and 4D. There was no significant impact of induction or maintenance lenalidomide on the 
evolutionary pattern seen at relapse, Supplementary Figure 7.  
We show that the depth of treatment response is the most important determinant of 
the evolutionary pattern seen at relapse. Although branching evolution was dominant in both 
the CR and non-CR series, stable progression was only seen in the non-CR series, (25% 
n=8/32 vs 0%, 0/25, p=0.008), Figure 5A. Breaking down the non-CR series further showed 
that stable progression was predominantly associated with a PR (56% (5/9) of PR and 13% 
(3/23) of VGPR patients). No CR or nCR patients (0/24) had evidence of stable progression, 
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with all patients showing branching or linear evolution (p=0.002), Figure 5B.  Consistent 
with a deep response being synonymous with a change in clonal architecture, 86% (6/7) of 
patients who achieved an MRD-ve state relapsed via a branching mechanism and 14% (1/7) 
via linear evolution. The type of evolution leading to relapse had no impact on the time to 
relapse or overall survival, Supplementary Table 6.   
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Discussion 
This study shows that an increase in mutational load, altered mutational profile, 
accumulation of deleterious structural lesions (particularly tMYC and gain(1q)), and a change 
in copy number profile are key molecular features of relapse. The depth of response to 
treatment has a significant impact on both the genetic landscape and the evolutionary 
patterns seen at relapse with an increased mutational load being predominantly associated 
with the achievement of a CR. We also note that relapse from CR is associated with an 
altered mutational profile with 63% (15/24) of the CR patients having evidence of loss or gain 
of known recurrently mutated genes in comparison to only 25% (8/32) of non-CR patients 
(p=0.006). This pattern was also seen for CNA and structural variants with del(17p), tMYC, 
gain(1q), and loss of tumour suppressor gene regions including CDKN2C, FAF1, FAM46C, 
RB1, and TRAF3 being seen more frequently in the patients relapsing from CR.  
 It has been shown that the progression through the multistep transformation of MM 
is associated with an increased mutational load. This is well illustrated by studies that have 
compared MGUS, MM and plasma cell leukaemia. Our results are consistent with this 
observation and we clearly show that an increased mutational load is an important factor in 
early disease progression following a good response to treatment (49, 50). Similar findings 
are observed in other cancer types where a greater mutational load is associated with a 
more aggressive disease state, for example lung cancer in smokers compared to non-
smokers and in malignant melanoma (51, 52).  
A variety of subclonal patterns, including branching, linear, and stable patterns, are 
seen at relapse, Figure 4A-D. The pattern of clonal change is most consistent with the 
hypothesis that branching evolutionary pathways are the predominant mechanism 
underlying relapse, especially if spatial variation is taken into account. Treatment can be 
seen as causing an evolutionary bottleneck, particularly in patients who achieve a deep 
treatment response, providing a selective pressure for the emergence of pre-existent 
resistant clones.  Importantly, these branching patterns and increased genetic damage in 
the clonal cells is the hallmark of effective treatment and the achievement of deep 
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responses. In contrast, the stable patterns seen in non-CR patients are most consistent with 
microenvironmental change, possibly as a consequence of the presence of innately 
treatment resistance dominant clones at disease onset, rather than the selection of 
“resistance mutations” as being the predominant mechanism for relapse. This stable pattern 
is reminiscent of the results seen in the progression of SMM to MM, where the emergence of 
new mutations is infrequent, yet there is a profound change in clinical behaviour. 
Mechanistically, relapse in the setting of effective therapy, that results in the 
achievement of a CR is occurring either due to the emergence of low level sub-clones 
undetectable at presentation, but which are selected for by the treatment or as a result of 
the acquisition of new mutations, albeit less likely given the short duration of remission.  It 
may also be that the sample bias resulted in the differences seen, as previously shown by 
our group, although this is less likely given all biopsies were obtained from the pelvis (53).  
The pattern of results seen with eradication of dominant clones and emergence of low level 
clones with different pattern of mutation and its association with CR supports the concept 
that treatment can result in subclonal eradication. These findings highlight the therapeutic 
importance of achieving a CR to eradicate dominant clones present at the initiation of 
therapy. Supporting this as a therapeutic aim, we have recently shown that high risk patients 
achieving a molecular CR have very significantly improved 5-year survival rates (54).  
The results show that even in CR and MRD-ve states, there are low level resistant 
subclones and that strategies need to be designed to address these therapeutically. We 
believe this work supports the current best practice strategy of using different treatment 
regimens at successive relapses and why this approach is successful. We show that early 
relapse is either due to innate treatment resistance, requiring no change in the clonal 
structure or due to a change of clonal architecture in response to effective therapy. Both 
mechanisms are consistent with a disease state at relapse that is resistant to the initial 
therapies used. This knowledge supports the use of combination regimens at relapse, 
incorporating agents with differing mechanisms of action to those used at presentation. A 
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comparator series looking at patients who achieved long-term remission is planned and as 
the trial matures this analysis will be undertaken. This work does however provide new 
insights into the mechanisms of relapse in early disease, revealing a different mechanism in 
those who achievement of a deep therapeutic response and those who do not.   
It is of interest that a recent study looking at non-small cell lung cancer has shown 
that mutational load my direct treatment choices, whereby the use of immunotherapy was 
associated with a longer and durable remission in patients with a greater mutational load at 
presentation (55). It may therefore be that as our understanding of myeloma biology 
increases information such as mutational load may guide specific treatment modalities in the 
future.  The use of Lenalidomide maintenance is the first clinical strategy to address the 
residual cells that remain following initial treatment. Using this approach, we did not see a 
signal of any adverse impact on the clonal cells, as a result of this therapy. In particular, we 
did not see a signal for selection of mutations that could confer resistance to the 
lenalidomide either at presentation or at relapse. Previous studies have suggested that such 
mutations may exist and could be relatively frequent in cell lines and heavily pre-treated 
patients but in this study of newly diagnosed patients they were rare (56). However, we do 
describe a patient who received 8 months of maintenance treatment, achieving an MRD-ve 
CR who did relapse with a new CRBN mutation. It is likely the mutation occurred by chance, 
but in true Darwinian fashion, in the presence of lenalidomide, it conferred a survival 
advantage to the malignant cells harbouring it. Recent analyses indicating that prolonged 
exposure to lenalidomide is not linked to an increased incidence of second primary 
haematological malignancies when used in combinations excluding oral melphalan may be 
supported by a lack of evidence of mutagenesis leading to treatment resistance in this work, 
although it is acknowledged that larger analyses using patients with prolonged remissions 
are required (24, 57). It is important to note that the patients studied here relapsed early and 
were selected for this behavior as it has previously been suggested that exposure to 
lenalidomide could enhance progression of such cases post-maintenance. We did not find 
any evidence to support such a hypothesis.  
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It does remain important to evaluate the impact of maintenance on low risk cases 
who are long term survivors, a question not addressed in this study. In addition we 
acknowledge that clonal structure may be further assessed using single cell analysis, but at 
present the challenges of obtaining individual malignant plasma cells from large series of 
patients at multiple disease time points has been a significant barrier. In this series of 
patients however we do see evidence of parallel evolution as previously described using 
single cell technology, further validating the clonal changes described here (23). An example 
is seen in a patient with bi-allelic inactivation of TP53 at presentation but only the presence 
of a TP53 mutation at relapse. In this case the clone with bi-allelic inactivation was no longer 
detectable at relapse, suggesting it was treatment sensitive and/or out-completed by a more 
aggressive treatment insensitive clone harbouring a TP53 mutation that had expanded 
following treatment, confirmed by a higher CCF at relapse (0.55 vs 0.83).  
In this group of high risk early relapsing patients, we show that relapse is a result of 
the dynamic interplay of evolutionary processes based around the adaptation of clonal cells 
capacity to their bone marrow microenvironment as a result of new mutations, copy number 
change and the selective pressure of the treatment used. Specifically, the depth of response 
is a critical feature that impacts the evolutionary patterns seen at relapse but this is not 
impacted by the use of maintenance lenalidomide.   
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Tables 
 
Table 1. Previous studies assessing clonal evolution in myeloma. 
Study Patients Disease 
status Technique Findings 
Keats et al.  
Blood  
(2012) (19) 
28 Presentation 
vs Relapse Array CGH 
Three major tumour types 
identifiable: 
   1. Genetically stable 
   2. Linear evolution 
   3. Heterogeneous clonal  
       mixtures and shifting  
       predominant clones. 
Magrangeas et al. 
Leukaemia  
(2013) (20) 
24 Presentation 
vs Relapse SNP array 
Branching evolution outlined 
as a cause for relapse in 1/3 
of patients. The remaining 
patients displayed linear and 
stable pathways to relapse. 
Bolli et al.  
Nat Commun  
(2014) (21) 
67 Presentation 
vs Relapse 
NGS/SNP 
array and 
cytogenetics 
Linear, branching, stable and 
differential clonal 
evolutionary responses 
described.  Description of 
kataegis and somatic 
hypermutation. 
Melchor et al. 
Leukaemia  
(2014) (23) 
6 Presentation 
vs Relapse 
NGS and 
single cell 
analysis 
Linear and branching 
evolution shown at a single 
cell level. 
Kortum et al.  
Ann Hematol 
(2015) (22) 
25 Presentation 
vs Relapse 
NGS gene 
panel 
Use of a targeted 
sequencing panel to 
demonstrate gain and loss of 
significantly mutated genes 
confirming clonal evolution. 
Weinhold et al. 
Blood  
(2016) (18) 
33 Presentation 
vs Relapse 
NGS and   
GEP 
Mutational load increases at 
relapse in association with 
an enrichment of driver gene 
mutations and bi-allelic TSG 
events. Branching evolution 
as the main mechanism 
leading to relapse. 
Abbreviations: CGH – comparative genomic hybridization, SNP – single nucleotide 
polymorphism, NGS – next generation sequencing, GEP – gene expression profiling.  
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Table 2. Series characteristics. 
  
Whole series 
(% of all) 
Maintenance randomisation 
Lenalidomide 
(% of group) 
Observation 
(% of group) 
Patient numbers 56 30 26 
Median age 68 67 69 
Gender        
Male 28 (50) 13 (43) 15 (58) 
Female 28 (50) 17 (57) 11 (42) 
Pathway        
TE 22 (39) 11 (37) 11 (42) 
TNE 34 (61)   19 (63) 15 (58) 
Induction        
Thalidomide 29 (52) 15 (52) 14 (48)  
Lenalidomide 27 (48) 15 (56) 12 (44) 
Best response       
       CR series (CR/nCR) 24 (43) 14 (47) 10 (38) 
       Non-CR series (VGPR/PR) 32 (57) 16 (53) 16 (62) 
Median maintenance duration 
(months, range) 10 (1-27) 10 (1-27) 9 (1-22) 
Median number of 
maintenance cycles (range) n/a 7 (1-28) n/a 
Median PFS (months, range) 19 (8-51) 19 (8-51) 19 (8-34) 
Presentation ISS       
I 13 (23) 5 (17) 8 (31) 
II 21 (38) 12 (40) 9 (35) 
III 21 (38) 12 (40) 9 (35) 
Missing 1 (2) 1 (3)   
Cytogenetic risk*       
High risk 20 (36) 12 (40) 8 (31) 
Ultra-high risk 7 (13) 5 (13) 2 (8) 
* High risk defined as one of t(4;14), t(14;16), t(14;20), gain(1q), and del(17p). Ultra-
high risk defined as two lesions. 
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Figure legends 
 
Figure 1. The mutational profile at presentation and relapse.  
A) Recurrent mutations in myeloma and mutations within the genes associated with 
immunomodulatory agent action. The number of patients with these mutations at 
presentation, relapse and at both time points is shown (dotted line denotes 10% level).  
B) Mutational profile for each patient at presentation and relapse. Maintenance strategy and 
best response prior to relapse is shown. The gain and loss of mutated genes typical of MM 
was a dominant feature. C) Summary of mutations gained and lost at relapse. New 
mutations at relapse were seen in PRDM1, TP53, NF1, TET2, EGFR, MYC, DDB1, CRBN, 
and FAF 1 (red bars). Loss of mutations in FANCA, DIS3, FAM46C, BRAF and CDH2 were 
noted at relapse (blue bars). Mutations in NRAS, KRAS, and SLC16A1 were gained and lost 
at relapse.  
 
Figure 2. The proportion of patients with a change in the profile of mutations known to 
be recurrent in myeloma or important in immunomodulatory mechanism of action at 
relapse. A) The proportion of all patients (n=56) with a change in the profile of recurrent 
mutations at relapse. The majority of CR series patients had a change in the mutational 
profile at relapse, 67% (16/24) vs 25% (8/32) of non-CR patients (p=0.003, Wilcoxon 
matched pairs). B) The proportion of observation patients (n=26) with a change in the profile 
of recurrent mutations at relapse. Only 19% (3/16) of non-CR observation patients had a 
change in the profile of mutations at relapse, compared to 70% (7/10) of CR observation 
patients (p=0.02). C) The proportion of lenalidomide maintenance patients (n=30) with a 
change in the profile of recurrent mutations at relapse. The same pattern of mutational 
profile change was seen in the lenalidomide maintenance patients, with 64% (9/14) of the 
CR patients having a mutational profile change at relapse compared to 31% of non-CR 
patients (p=0.14).  
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Figure 3. Number of mutational clusters at presentation and relapse. A) For all 56 
patients the number of mutational clusters was similar at presentation and relapse. The 
same pattern was seen irrespective of maintenance strategy (B and C) and depth of 
response (D and E). This suggests a change in clonal number is not a major factor in 
disease progression.  
 
Figure 4. The evolutionary patterns seen leading to relapse.  
A) Branching: Branching evolution was the predominant mechanism seen and was 
characterised both by the gain and loss of mutational clusters at relapse. The CCF for all 
coding mutations using kernel density estimation for a typical patient (left image) is shown 
and reveals the presence of a new dominant PRDM1 (CCF 1.0) containing clone at relapse 
only (each dot represents a mutation). In addition a CHD2 (CCF 0.91 presentation only) 
containing clone is lost at relapse whilst an NRAS containing clone remained dominant at 
presentation (CCF 1.0) and relapse (CCF 0.99). The right sided image is an illustration of the 
branching evolutionary process using the same patient. Prior to treatment there are a 
number of competing sub-clones but as a result of effective therapy, clonal extinction occurs 
leading to a genetic bottleneck. This leads to the emergence of a new clonal structure at 
relapse, in this case the loss of a dominant CHD2 clone, the gain of a PRDM1 clone and a 
stable NRAS clone. In addition the emergence of a new DDB1 mutation was seen within a 
minor clone with a CCF of 0.21.  
B) Linear: Linear evolution was seen in 20% of patients, characterised by the gain of 
mutations at relapse but no evidence of clonal loss. The KDE plot is displayed and shows 
the emergence of a new clonal PRDM1 mutation at relapse with a CCF of 1.0. The right 
sided illustration shows that over time, successive generation of daughter cells acquire 
aberrations making them genetically distinct, in this example the emergence of a new 
PRDM1 mutation.  
C) Stable progression: The left KDE plot shows a typical patient with stable progression, 
revealing a preserved clonal structure at both time points, with CCF values for all mutations 
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remaining consistent at both time points. The CHD2 mutation was present within a dominant 
clone at presentation and relapse with a CCF of 0.83 and 0.87 respectively. Stable evolution 
was a characteristic of patients achieving a non-CR, particularly a PR. These patients 
appeared to have a treatment resistant disease state and therefore the emergence of the 
same clonal structure was seen at relapse as seen at disease onset. This is illustrated by the 
right side schematic, in this case with a CHD2 dominant clone at both time points.  
D) Stable with loss was seen in one patient and kernel density estimation revealed the 
presence of a predominantly preserved clonal structure at relapse with clusters containing 
TRAF3 and LTB present with similar CCF values at both points. There was evidence of the 
loss of a cluster of mutations at relapse, suggestive of clone loss (circled). The schematic 
illustrates the evolutionary process. Treatment sensitive clone(s) are eliminated but the 
resistant clone(s) remain and lead to the relapse disease state.  
 
Figure 5. The evolutionary patterns seen leading to relapse according the depth of 
treatment response.  
A) The evolutionary mechanism leading to relapse for the CR and non-CR series. 
Stable evolution was only seen in the non-CR patients (Fishers exact test p=0.008).  
Branching evolution was the predominant mechanism leading to relapse in both CR and 
non-CR patients, with linear evolution also occurring, but in a smaller proportion of patients. 
B) The evolutionary mechanism leading to response according the depth of response. 
Over half (56%) of the patients who achieved a PR as their best response prior to relapse 
progressed via a stable mechanism (p=0.002). A smaller proportion of VGPR patients 
displayed stable progression (13%). Branching evolution was dominant, seen in 75% of nCR 
patients and 67% of CR patients. 
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Supplementary Table 1. Characteristics according to induction treatment 
  
Induction 
Lenalidomide 
(% of group) 
Thalidomide 
(% of group) 
Patient numbers 27 (52) 29 (48) 
Best response     
CR series (CR/nCR) 12 (44) 12 (41) 
Non-CR series 
(VGPR/PR) 
15 (56) 17 (59) 
Median PFS  
(months,  range) 
19 (8-51) 19 (8-34) 
Presentation ISS     
I 6 (22) 7 (24) 
II 11 (41) 10 (34) 
III 10 (37) 11 (38) 
Missing   1 (3) 
Evolutionary mechanism     
Branching 20 (74) 17 (59) 
Linear 3 (11) 8 (28) 
Stable 4 (15) 4 (14) 
Non-synonymous mutational 
load  
    
Presentation 37 40 
Relapse 41 58 
All coding mutations      
Presentation 70 81 
Relapse 86 102 
 
 
  
Supplementary Table 2. The profile of mutations known to be important in myeloma at 
presentation and relapse according to induction therapy. Mutations in KRAS, NRAS, DIS3, FAM46C, 
TET2, TRAF3 and TP53 were seen in >5% of patients at either time point in both series. Mutations 
were gained and lost at relapse in both the lenalidomide and thalidomide series. 
Lenalidomide induction   Thalidomide induction 
Gene Presentation Relapse   Gene Presentation Relapse 
KRAS 26 (7) 30 (8)   NRAS 21 (6) 24 (7) 
NRAS 30 (8) 22 (6)   KRAS 17 (5) 17 (5) 
DIS3 22 (6) 19 (5)   TP53 10 (3) 14 (4) 
RB1 15 (4) 15 (4)   TRAF3 10 (3) 10 (3) 
ATM 7 (2) 7 (2)   DIS3 7 (2) 7 (2) 
FAM46C 7 (2) 7 (2)   NF1 3 (1) 7 (2) 
TET2 7 (2) 7 (2)   TET2 3 (1) 7 (2) 
TRAF3 7 (2) 7 (2)   FAM46C 7 (2) 3 (1) 
EGFR 4 (1) 7 (2)   PRDM1 0 7 (2) 
TP53 4 (1) 7 (2)   ATM 3 (1) 3 (1) 
DDB1 4 (1) 7 (2)   ATR 3 (1) 3 (1) 
BRAF 7 (2) 4 (1)   HIST1H1E 3 (1) 3 (1) 
NF1 4 (1) 4 (1)   CHD2 3 (1) 3 (1) 
LTB 4 (1) 4 (1)   RB1 3 (1) 3 (1) 
ATR 4 (1) 4 (1)   EGR1 3 (1) 3 (1) 
HIST1H1E 4 (1) 4 (1)   FGFR3 3 (1) 3 (1) 
SETD2 4 (1) 4 (1)   IRF4 3 (1) 3 (1) 
SLC16A1 4 (1) 4 (1)   CRBN 0 3 (1) 
EGR1 4 (1) 4 (1)   MYC 0 3 (1) 
FGFR3 4 (1) 4 (1)   FAF1 0 3 (1) 
IRF4 4 (1) 4 (1)   FANCA 3 (1) 0 
PRDM1 0 4 (1)   SETD2 0 0 
CHD2 4 (1) 0   DDB1 0 0 
FANCA 4 (1) 0   SLC16A1 0 0 
CRBN 0 0   BRAF 0 0 
FAF1 0 0   EGFR 0 0 
MYC 0 0   LTB 0 0 
              
Mutations in bold indicates they were seen in >5% of patients at either presentation or relapse in both series. 
 
Supplementary Table 3. MYC translocations at presentation and relapse 
Patient MYC time point  
IGH 
translocation 
1st 
Chr. 
1st gene 2nd Chr. 2nd gene Induction Maintenance 
Best 
response 
Presentation and relapse 
7* Presentation and relapse 14;16 P+R 16 WWOX 8 LOC727677-MYC 
CTD Lenalidomide VGPR 
7* Presentation and relapse 14;16 P+R 14 BRF1 8 PVT1-LOC728724 
11 Presentation and relapse Nil 14 C14orf80-TMEM121 8 POU5F1B-LOC727677 RCD Lenalidomide VGPR 
12* Presentation and relapse Nil 15 BCL2A1-ZFAND6 8 PVT1   
CTDa Lenalidomide PR 
12* Presentation and relapse Nil 21 PRDM15 8 PVT1-LOC728724 
29 Presentation and relapse Nil 5 ZNF131 8 LOC727677 RCDa Lenalidomide VGPR 
34* Presentation and relapse 10;14 P only 9 SYK 8 LOC727677-MYC 
CTD Observation VGPR 
34* Presentation and relapse 10;14 P only 2 EIF2AK-RPIA 8 MYC-PVT1 
36 Presentation and relapse 14;19 P only 22 TTC28 8 PCAT1-POU5F1B RCD Observation PR 
38 Presentation and relapse Nil 22 TTC28 8 PCAT1-POU5F1B RCDa Observation nCR 
42* Presentation and relapse Nil 1 FAM46C 8 PVT1 
CTDa Observation PR 
42* Presentation and relapse Nil 1 FAM46C 8 PVT1 
46 Presentation and relapse Nil 4 TMEM155 8 PVT1-LOC728725 CTD Observation PR 
55 Presentation and relapse Nil 6 DUSP22 8 PVT1-LOC728725 CTD Observation VGPR 
56 Presentation and relapse 11;14 P+R 14 ELK2AP-KIAA0125 8 LOC727677-MYC CTD Observation VGPR 
Relapse only 
18* Relapse only 14;16 P+R 2 LAPTM4A-SDC1 8 PVT1-LOC728724 
CTDa Lenalidomide CR 
18* Relapse only 14;16 P+R 22 IGLL5-RTDR1 8 PVT1-LOC728724 
31 Relapse only Nil 22 IGLL5-RTDR1 8 PVT1-LOC728724 RCDa Observation CR 
47 Relapse only 11;14 P+R 7 COBL-POM121K12 8 PVT1 CTDa Observation VGPR 
Loss and gain 
53* Presentation only Nil 22 IGLL5-RTDR1 8 PVT1-LOC728725 
CTDa Observation nCR 
53* Relapse only Nil 3 SPTA16-NLGN1 8 PCAT1-POU5F1B 
Supplementary Table 4. Mutational load according to depth of response and maintenance allocation 
 
Treatment/time point 
Median 
number of 
mutations  
Interquartile range p value 
CR series - all mutations and non-synonymous mutations only 
Lenalidomide all Presentation 82 59 - 271 
0.046 
n=14 Relapse 117 80 - 288 
Lenalidomide NS Presentation 42 25 - 110 
0.01 
n=14 Relapse 58 41 - 124 
Observation all Presentation 65 53 - 95 
0.07 
n=10 Relapse 93 64 - 152 
Observation NS Presentation 38 30 - 52 
0.09 
n=10  Relapse 59 32 - 78 
Whole series all Presentation 76 58 - 115 
0.008 
n=24 Relapse 102 71 - 177 
Whole series NS Presentation 40 29 - 52 
<0.001 
n=24 Relapse 59 40 - 81 
Non-CR series 
Lenalidomide all Presentation 64 54 - 86 
0.68 
n=16 Relapse 67 44 - 87 
Lenalidomide NS Presentation 37 26 - 46 
0.75 
n=16 Relapse 37 22 - 44 
Observation all Presentation 85 69 - 107 
0.59 
n=16 Relapse 97 69 - 140 
Observation NS Presentation 45 34 - 54 
0.56 
n=16 Relapse 51 33 - 77 
Whole series Presentation 71 60 - 105 
0.53 
n=32 Relapse 82 60 - 117 
Whole series Presentation 39 32 - 54 
0.56 
n=32 Relapse 39 33 - 62 
NS = Non-synonymous 
All = all coding mutations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 5. Mutational clusters at presentation and relapse 
 
  Patient Maintenance Cluster change at 
relapse 
Clusters 
presentation 
Clusters 
relapse 
1 Lenalidomide Gain 7 8 
2 Lenalidomide Neutral 4 4 
3 Lenalidomide Gain 8 10 
4 Lenalidomide Gain 8 9 
5 Lenalidomide Neutral 4 4 
6 Lenalidomide Neutral 7 7 
7 Lenalidomide Neutral 6 6 
8 Lenalidomide Neutral 8 8 
9 Lenalidomide Neutral 7 7 
10 Lenalidomide Neutral 10 10 
11 Lenalidomide Loss 7 6 
12 Lenalidomide Neutral 7 7 
13 Lenalidomide Loss 8 7 
14 Lenalidomide Loss 5 4 
15 Lenalidomide Neutral 5 5 
16 Lenalidomide Neutral 2 2 
17 Lenalidomide Neutral 3 3 
18 Lenalidomide Neutral 9 9 
19 Lenalidomide Neutral 4 4 
20 Lenalidomide Gain 6 6 
21 Lenalidomide Neutral 9 9 
22 Lenalidomide Loss 3 2 
23 Lenalidomide Gain 6 7 
24 Lenalidomide Gain 5 6 
25 Lenalidomide Neutral 7 7 
26 Lenalidomide Neutral 6 6 
27 Lenalidomide Neutral 6 6 
28 Lenalidomide Gain 7 8 
29 Lenalidomide Neutral 4 4 
30 Lenalidomide Neutral 7 7 
31 Observation Neutral 4 4 
32 Observation Loss 10 9 
33 Observation Neutral 5 5 
34 Observation Gain 8 9 
35 Observation Gain 7 8 
36 Observation Loss 8 7 
37 Observation Neutral 8 8 
38 Observation Gain 6 7 
39 Observation Neutral 6 6 
40 Observation Loss 4 5 
41 Observation Loss 6 5 
42 Observation Neutral 6 6 
43 Observation Neutral 7 7 
44 Observation Gain 4 5 
45 Observation Gain 3 4 
46 Observation Neutral 5 5 
47 Observation Neutral 10 10 
48 Observation Neutral 4 4 
49 Observation Gain 6 7 
50 Observation Loss 5 3 
51 Observation Loss 8 7 
52 Observation Gain 3 4 
53 Observation Neutral 9 9 
54 Observation Neutral 6 6 
55 Observation Neutral 7 7 
56 Observation Gain 7 8 
Supplementary Table 6 – Impact of evolution on outcome according to maintenance allocation 
Treatment group Time point PFS p value OS p value 
Lenalidomide  
Branching 19 
0.69 
36 
0.58 
Non-branching 18 36 
Observation 
Branching 22 
0.18 
46 
0.73 
Non-branching 16 44 
All patients 
Branching 19 
0.24 
37 
0.13 
Non-branching 16 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1.  Pathway for all patients included in the nested case control analysis.  
Abbreviations; TE, transplant eligible; TNE, transplant non-eligible; CTD, cyclophosphamide, thalidomide 
and dexamethasone; RCD, lenalidomide, cyclophosphamide and dexamethasone; a, attenuated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2.  Analysis pipeline. Following preparation and indexing all samples were run on the Illumina 
HiSeq 2500. Conversion of BCL files to compressed Fastq files required de-multiplexing (for pooled samples) which 
was conducted using the package CASAVA v1.8.4 (Illumina). The package FASTQC (version 0.11, Babraham 
Bioinformatics) was used for basic quality checking of all Fastq files. All files were aligned to the reference human 
genome (GRCh37) using Burrow-Wheeler Aligner (BWA-mem version 0.7.12 (Broad institute)). This consists of a 
package of three algorithms that enable mapping of reads from between 70 bp – 1Mbp (1, 2). Additional indexing steps 
were conducted using Sambamba (version 0.5.6, GitHub), to index and mark duplicates and the Genome Analysis 
Toolkit (version 3.5, GATK) for base recalibration and indel realignment (3). Determination of coverage, number of 
duplicates and on-target percentage was performed using Picard (version 1.119, Broad institute).   
Translocations involving the IgH and MYC locus were determined in all patients using the bioinformatics package 
Manta (version 0.29.3) (4). For 51/112 (46%) patient samples, for which enough DNA was available, translocations 
involving the IgH were also assessed using multiplexed real-time quantitative reverse transcriptase-PCR (qRT-PCR) 
and a fluorescence in-situ hybridisation-validated translocation analysis using a cyclin-D classification-based 
hierarchical algorithm was applied to determine the IgH translocation status (5).  This formed an internal quality control 
and a consensus between MANTA and qRT-PCR was observed in 43/51 samples (84%).  For the 8 patients where a 
mismatch was observed the Integrative Genomics Viewer (IGV) (version 2.3.90) was used to confirm whether a 
translocation was present or not (6). IGV was used to confirm all suspected MYC translocations. 
CNAs for all samples were determined using the bioinformatics assessment tool Sequenza (version 2.1.2, CRAN) 
and where there was enough DNA multiplexed ligation-dependent probe amplification (MLPA) (SALSA MLPA P425-B1 
multiple myeloma probemix, MRC Holland) was also undertaken (7, 8). Paired MLPA and Sequenza data was available 
for 90/112 (80%) tumour samples.  A consensus between MLPA and Sequenza was observed in 85/90 samples (94%).  
For the five patients where a mismatch was observed Sequenza was used to determine the final profile. 
Single nucleotide variants and indels were identified using MuTect (version 1.1.17, broad) and Strelka (version 
1.0.14, GitHub) using the default settings (9, 10). Filtering of MuTect output was undertaken with fpfilter (github.com) 
with a set variant allele frequency (VAF = reference allele/variant allele corrected for copy number) threshold of 5%. 
Indels were called using Strelka only (VAF filter 5%). A VAF filter was required to ensure mutations were not called 
inappropriately, as a consequence of low level cross contamination or sequencing errors. Single nucleotide variants 
located with the immunoglobulin loci were excluded due to expectant non-significant variation. The R package 
Rsamtools (version 1.24.0, Bioconductor) for aligned sequences was used to determine read counts for each mutation. 
The set inclusion criteria for mutation calling included; the presence of unique reads, a mapping quality of a minimum of 
20 reads and the same for base quality at variant sites and a minimum coverage of 50x for presentation, relapse and 
control samples for the patient. Non-silent mutations were defined as missense, frameshift, non-sense, and splice site.  
     For all mutations the CCF was calculated according to Stephens et al (2012) (11). To determine the CCF the 
copy number at the mutation site, tumour purity and VAF was required and the following equation applied; 
 
𝑛𝑚𝑢𝑡 =  ƒ𝑠 ∗  
1
𝑝
 [𝑝𝑛𝑙𝑜𝑐𝑢𝑠
𝑡 + 2(1 − 𝑝)] 
 
Where; 𝑛𝑚𝑢𝑡 = mutation copy number, ƒ𝑠 = VAF, 𝑝 = tumour purity, 𝑛𝑙𝑜𝑐𝑢𝑠
𝑡
 = mutation site copy number 
Purity and mutation site copy number where determined using Sequenza, with purity manually checked against the 
mutant allele frequency on Chromosome 14. The expected VAF was compared to values assuming the mutation was 
on 1, 2, …., C chromosomes and assigned 
n
chr  the value of C with binomial distribution used to determine the 
maximum likelihood. The CCF was then calculated by dividing 
n
mut by 
n
chr. 
SciClone clustering, using the VAF for all coding mutations (R package version 1.1.0, GitHub) was performed to 
infer clusters of mutations in all patients at presentation and relapse (12). In addition, kernel density estimation plots for 
determining clusters of mutations according to CCF was used (R package).  
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Supplementary Figure 3. Cancer clonal fractions of RAS pathway mutations gained and lost at relapse. 
New mutations of the MAPK pathway genes, NRAS, KRAS, NF1 and EGFR were seen in 13% (7/56) patients 
at relapse. Importantly most of these new mutations were clonal at relapse, with CCF values of greater than 
80%, suggesting a marked change in clonal dominance. Mutations in NRAS, KRAS and BRAF were also lost 
in 9% (5/56) patients at relapse. 
 
  
  
 
Supplementary Figure 4. Structural aberration profile at presentation and relapse. The number of 
patients with one or more prognostic tumour suppressor gene deletion remained stable at both time points, 
with 63% (35/56) of patients having a deletion or one or more region at presentation compared to 59% 
(33/56) at relapse. There was a slightly higher proportion of patients with three or more deleted regions at 
relapse, 16% versus13% at presentation.  
 
  
  
 
Supplementary Figure 5. Proportion of patients with structural change at presentation and relapse. A) 
CR series. A change in the profile of structural aberrations was seen in 42% (10/24) of the CR patients at 
relapse when compared to presentation. The gain of lesions predominated, particularly tMYC, del(17p), del(1p) 
and gain(1q), all of which were seen in a greater proportion of patients at relapse. B) Non-CR series. Only 
28% of non-CR patients had a change in the structural aberration profile at relapse, with only gain(1q) and 
del(1p) seen in a greater proportion of patients when compared to presentation.   
 
  
  
 
Supplementary Figure 6. CRBN mutation cancer clonal fraction at presentation and relapse. At 
presentation no CRBN was evident but at relapse a new mutation was found with a CCF of 0.71 suggesting 
it was present within a dominant clone at relapse.  
 
  
  
Supplementary Figure 7. Evolutionary mechanism leading to relapse according to induction and maintenance 
randomisation. A) Evolution according to maintenance. Branching evolution was the predominant mechanism 
leading to relapse, seen in 54% of observation patients and 77% of lenalidomide maintenance patients (p=0.09, 
Fisher’s Exact). There was also no statistical difference between the proportions of patients relapsing via linear and 
stable mechanisms. B) Evolution according to induction. Branching evolution was the predominant mechanism 
leading to relapse, seen in 59% of thalidomide treated patients and 74% of lenalidomide treated patients (p=0.27). 
Although there was a slightly higher proportion of thalidomide patients displaying linear evolution, 28% vs 11%, this 
was not significant (p=0.18). Stable progression was seen in 14% and 15% of thalidomide and lenalidomide patients 
respective (p=1.0).  
 
 
